1. Home /
    2. Altai Protocol Library /
  2. New Indication: Pembrolizumab plus Lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Pembrolizumab plus Lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma

New Indication: Pembrolizumab plus Lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma
Study:
  • Single-arm, open-label, multicenter, phase II trial
  • Previously untreated stage IV non-clear cell renal cell carcinoma
  • Pembrolizumab + Lenvatinib (n=158)
Efficacy:
  • cORR: 49% [78 of 158 pts]
  • CR: 6% [ 9 of 158 pts]
  • mPFS: 18.0 mos [14-NR]
  • 12 mPFS: 63% [54-70]
  • 12 mOS: 82% [72-88]
Safety:
  • Grade≥3: Hypertesion (23%), proteinuria (4%), stomatitis (4%)

LANCET Oncol, VOL 24, ISSUE 8, P881-891, AUG 2023

Albiges L et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

http://doi.org/10.1016/S1470-2045(23)00276-0

Reviewed by Elvin CHALABİYEV, MD on AUG 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More